Vacthera BioTech GmbH logo

Vacthera BioTech GmbH

Vacthera is a biotechnology company developing influenza virus based vaccines and cancer immuno therapies. Vacthera's platform technology enables the generation of stable influenza virus vaccine vectors that can be produced at high yields.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.vacthera.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
An der Wehr 6 2440
Reisenberg
Austria
Email
Contact Number
+ 436769303370

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/vacthera” connections=”true” suffix=””]

Oncolytic viruses are a novel type of tumor immunotherapy complementing standard therapies including checkpoint inhibitors. Viruses are engineered to conditionally replicate in cancer tissue leading to tumor destruction by stimulation of the immune system. The founders of Vacthera were the first to generate an oncolytic virus for the influenza virus family. Currently the development is in a preclinical stage.